DrugPatentWatch Database Preview
Drugs in Development Information for HIP1402
» See Plans and Pricing
What is the drug development status for HIP1402?
HIP1402 is an investigational drug.
There have been 5 clinical trials for HIP1402.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Prostatic Hyperplasia, Hyperplasia, and Erectile Dysfunction. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited and [disabled in preview].
There is one US patent protecting this investigational drug and fifteen international patents.
Summary for HIP1402
| US Patents | 1,715 |
| International Patents | 15,549 |
| US Patent Applications | 3,531 |
| WIPO Patent Applications | 2,057 |
| Japanese Patent Applications | 24 |
| Clinical Trial Progress | Phase 3 (2014-10-01) |
| Vendors | 59 |
Recent Clinical Trials for HIP1402
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 |
| PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 |
Clinical Trial Summary for HIP1402
Top disease conditions for HIP1402
Top clinical trial sponsors for HIP1402
US Patents for HIP1402
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HIP1402 | Start Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| HIP1402 | Start Trial | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA) | Start Trial |
| HIP1402 | Start Trial | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| HIP1402 | Start Trial | Matrix and layer compositions for protection of bioactives | Novus International, Inc. (St. Charles, MO) | Start Trial |
| HIP1402 | Start Trial | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | Start Trial |
| HIP1402 | Start Trial | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (New Haven, CT) | Start Trial |
| HIP1402 | Start Trial | Substituted pyridazines for the treatment of pain | INHIBITAXIN LIMITED (Sandwich Kent, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HIP1402
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HIP1402 | European Patent Office | 2981556 | 2033-04-02 | Start Trial |
| HIP1402 | World Intellectual Property Organization (WIPO) | 2014165513 | 2033-04-02 | Start Trial |
| HIP1402 | China | 106715418 | 2034-07-07 | Start Trial |
| HIP1402 | European Patent Office | 3166939 | 2034-07-07 | Start Trial |
| HIP1402 | Japan | 2017525677 | 2034-07-07 | Start Trial |
| HIP1402 | World Intellectual Property Organization (WIPO) | 2016007534 | 2034-07-07 | Start Trial |
| HIP1402 | Australia | 2015210983 | 2034-01-30 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
